EPFL

PharmaVentures advises Lausanne Hospital (CHUV) and EPFL on their collaboration and founding of Aerium Therapeutics to develop their highly potent SARS-CoV-2 antibodies

Retrieved on: 
Thursday, March 24, 2022
Aerium, Therapy, Vaccination, Omega, Lausanne University Hospital, Volatile organic compound, EPFL, Research, Delta, CEO, Severe acute respiratory syndrome coronavirus 2, Immunology, CHUV, Omicron, Neutralizing antibody, COVID-19, Series, Patient, Antibody, Vaccine, Medicine

Aerium Therapeutics is focused on discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2.

Key Points: 
  • Aerium Therapeutics is focused on discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2.
  • The company has recently emerged with substantial Series A financial backing by the founding investor Omega Funds with the participation of F-Prime Capital.
  • Aerium was seeded and incubated by Omega Funds in 2021 and started in collaboration with its two scientific founders, Dr. Giuseppe Pantaleo (CHUV) and Dr. Didier Trono (EPFL) in Switzerland.
  • In addition to its antiviral properties, the antibody has been designed to provide protection to those patients most vulnerable.

PharmaVentures advises Lausanne Hospital (CHUV) and EPFL on their collaboration and founding of Aerium Therapeutics to develop their highly potent SARS-CoV-2 antibodies

Retrieved on: 
Thursday, March 24, 2022
Aerium, Therapy, Vaccination, Omega, Lausanne University Hospital, Volatile organic compound, EPFL, Research, Delta, CEO, Severe acute respiratory syndrome coronavirus 2, Immunology, CHUV, Omicron, Neutralizing antibody, COVID-19, Series, Patient, Antibody, Vaccine, Medicine

Aerium Therapeutics is focused on discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2.

Key Points: 
  • Aerium Therapeutics is focused on discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2.
  • The company has recently emerged with substantial Series A financial backing by the founding investor Omega Funds with the participation of F-Prime Capital.
  • Aerium was seeded and incubated by Omega Funds in 2021 and started in collaboration with its two scientific founders, Dr. Giuseppe Pantaleo (CHUV) and Dr. Didier Trono (EPFL) in Switzerland.
  • In addition to its antiviral properties, the antibody has been designed to provide protection to those patients most vulnerable.

Aerium Therapeutics launches to develop novel therapeutics against COVID-19 and future pandemic threats

Retrieved on: 
Tuesday, March 22, 2022
Aerium, Pantaleo, Therapy, Vaccination, DRS, Degenerative disease, Medtech, Leadership, Multimedia, Board, Omega, Health care, Vaccine, Volatile organic compound, EPFL, Research, White, Delta, Capital, Severe acute respiratory syndrome coronavirus 2, Precision medicine, CEO, AstraZeneca, Immunology, Merck & Co., White House, CHUV, Omicron, Technology, Neutralizing antibody, Virology, COVID-19, Trono, Montreux Healthcare Fund, Series, BioRxiv, Bill & Melinda Gates Foundation, FDA, Director, History, Partnership, Antibody, Financial services, Management, Pharmaceutical industry, Medicine, Takeda, Coalition for Epidemic Preparedness Innovations, Pfizer, Ultragenyx, Tropical Islands Resort, Genetics

While we are initially assisting populations vulnerable to COVID-19 in the prophylactic and therapeutic settings, our overall vision is to develop effective therapeutics against not just existing but also future epidemic and pandemic threats."

Key Points: 
  • While we are initially assisting populations vulnerable to COVID-19 in the prophylactic and therapeutic settings, our overall vision is to develop effective therapeutics against not just existing but also future epidemic and pandemic threats."
  • Aerium Therapeutics has assembled a growing team of proven life science and enterprise leaders including:
    CEO Rajeev Venkayya, M.D.
  • Aerium Therapeutics is dedicated to epidemic and pandemic preparedness through the discovery and development of antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats.
  • The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future.

AMF Medical Names Markus Kohli, PhD Industrialization and Production Director

Retrieved on: 
Wednesday, March 9, 2022
Marketed Health Products Directorate, Budget, ETHZ, Product, FDA, American Physical Society, Diabetes, Insulin, EPFL, Board, CAPEX, Federal Institute for Drugs and Medical Devices, STC, Board of directors, Master of Science, Doctor of Philosophy, US Foods, Nestle Nigeria, Materials science, Environment, Food, Goal, Medical device, Pharmaceutical industry, Physics, Technology, Swiss, Director

"AMF Medical is building on the momentum from 2021 by preparing for the company's next major turning point.

Key Points: 
  • "AMF Medical is building on the momentum from 2021 by preparing for the company's next major turning point.
  • Markus Kohli's vast experience across multiple industries makes him the perfect choice to lead this process," said AMF Medical co-CEO Mr. Pim van Wesel.
  • Dr. Kohli joins AMF Medical from Xsensio SA where he was the Director of Product Development & Industrialization.
  • AMF Medical Co-CEO & Co-Founder Mr.Antoine Barraudsaid, "Markus Kohli has the track record needed to lead the transition of Sigi from development to scale up.

Prokarium Exercises Option for an Exclusive Worldwide License for the Use of Salmonella Immunotherapy in the Treatment of Bladder Cancer

Retrieved on: 
Wednesday, March 2, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Lausanne, Immunotherapy, Research, Hospital, Swiss Federal Institute of Aquatic Science and Technology, Quality of life, Doctor of Philosophy, Lausanne University Hospital, CHUV, Bacillus, BCG, University, Medicine, Bladder cancer, Department of Urology, University of Virginia, Cancer, Swiss, EPFL, Kinetics, Faculty, Gold, Incidence, Education, Department, Achievement, Swiss Federal Institute of Technology, Fine chemical, Medical imaging, Salmonella, Newsweek, Biology, NMIBC, Non-Muscle Invasive Bladder Cancer (NMIBC), the Lausanne University Hospital - CHUV, NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC), THE LAUSANNE UNIVERSITY HOSPITAL - CHUV

Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, announced today it exercised its option with Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois CHUV) for an exclusive, worldwide license for the use of Salmonella immunotherapy in the treatment of bladder cancer.

Key Points: 
  • Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, announced today it exercised its option with Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois CHUV) for an exclusive, worldwide license for the use of Salmonella immunotherapy in the treatment of bladder cancer.
  • Microbial immunotherapy is the gold standard-of-care in the treatment of bladder cancer.
  • Prokarium is introducing a differentiated, efficacious microbial immunotherapy to a market that has seen little disruption in over 30 years.
  • Bladder cancer represents 5% of all new cancer cases in the US and accounts for 550,000 new cases yearly worldwide.

GliaPharm SA and the Wyss Center Enter Collaboration to Develop New Therapies for Alzheimer’s Disease

Retrieved on: 
Thursday, February 24, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Genetics, Clinical Trials, Wyss Center for Bio and Neuroengineering, Lists of diseases, Glucose, Comparison, École Polytechnique, Campus Biotech, Glucose transporter, Drug development, EPFL, Disease, Bio, Neuron, Alzheimer's disease, Biomarker, Neurodegeneration, Brain, Neuroimaging, Wyss, Research, Neuroscience, Pharmaceutical industry, Medical imaging, GliaPharm, the Wyss Center for Bio and Neuroengineering, Geneva, Switzerland, GLIAPHARM, THE WYSS CENTER FOR BIO AND NEUROENGINEERING, GENEVA, SWITZERLAND

One of the hallmarks of neurodegenerative diseases such as Alzheimers is reduced glucose uptake by the brain, known as hypometabolism.

Key Points: 
  • One of the hallmarks of neurodegenerative diseases such as Alzheimers is reduced glucose uptake by the brain, known as hypometabolism.
  • The collaboration with the Wyss Center will allow us to accelerate our drug development towards other neurological indications that are linked to brain metabolism dysfunction, such as Alzheimer's disease.
  • GliaPharm will test the impact of its lead candidates in preclinical models of Alzheimers disease to advance the compounds towards clinical stage.
  • The Wyss Center was established by a generous donation from the Swiss entrepreneur and philanthropist Hansjrg Wyss in 2014.

Yves Perrin hands over management of HIAG Romandie to Patrick Japhet

Retrieved on: 
Tuesday, February 22, 2022
EPF, Yves, Board of directors, HIAG, Retirement, Board, EPFL, Institute, Director, Bouygues, Management

Basel, 22 February 2022 - Patrick Japhet will take over the management of HIAG Romandie on 1 May 2022.

Key Points: 
  • Basel, 22 February 2022 - Patrick Japhet will take over the management of HIAG Romandie on 1 May 2022.
  • Patrick Japhet joins HIAG from a family office active in the real estate business, where he held the position of Chief Operating Director and member of the Investment Committee.
  • Over the past twelve years, Yves Perrin has very successfully built up HIAG Romandie with his great know-how and a strong position in the real estate market of Western Switzerland.
  • HIAG's Board of Directors and Executive Board like to thank Yves Perrin for his valuable commitment and wish him all the best.

Qrypt Provides Secure Alternative to Quantum Key Distribution

Retrieved on: 
Tuesday, February 15, 2022
Networks, Security, Data Management, Technology, Software, Algorithm, Oak Ridge National Laboratory, Physics, Entropy, Science, QKD, AES, Solution, Key generation, Technology, EPFL, Von Neumann entropy, SDK, Los Alamos National Laboratory, Privacy, Computer, ICFO, Engineering, Research, BLAST, Organization, Cryptocurrency

Qrypt Key Generation can be applied in any cloud connected use case, leaving the alternative Quantum Key Distribution (QKD) for niche applications.

Key Points: 
  • Qrypt Key Generation can be applied in any cloud connected use case, leaving the alternative Quantum Key Distribution (QKD) for niche applications.
  • With this new solution, Qrypt is taking direct aim at the secure distribution problem by avoiding distribution altogether.
  • Qrypts Key Generation offers high speed, high-volume quantum key generation to keep up with the growing security needs of enterprises.
  • BLAST enables Key Generation to securely produce any kind of symmetric keys at multiple endpoints, including AES, negating the need for key encapsulation or key distribution.

MindMaze Powers Landmark Multidisciplinary Consortium to Develop State-of-the-Art Neuro-therapeutic Program Following Receipt of Prestigious CHF 5.9 Million Grant

Retrieved on: 
Tuesday, February 15, 2022
Hospitals, General Health, Health, Mental Health, TBI, Patient, Traumatic brain injury, CEO, University Hospital (Newark, New Jersey), Encarta, Ibuprofen brand names, Single-frequency network, Stroke, ETHZ, Solution, Rehabilitation, HES-SO, Unicorn, Therapy, University, EPFL, CARA, SCI, Lists of diseases, Association, Neurology, Teaching hospital, Artificial intelligence, FDA, Neuro, Data management, Research, Government budget balance, School, Caregiver, CE, Pharmaceutical industry, Medical imaging, Engineering

The SwissNeuroRehab group will leverage the over CHF11.2 million (USD12.2 million) award to build state-of-the-art, evidence-based, effective and efficient therapeutic programs integrating digital therapeutics and neurotechnology along the continuum of care.

Key Points: 
  • The SwissNeuroRehab group will leverage the over CHF11.2 million (USD12.2 million) award to build state-of-the-art, evidence-based, effective and efficient therapeutic programs integrating digital therapeutics and neurotechnology along the continuum of care.
  • SwissNeuroRehab is the latest in MindMazes ongoing efforts to participate in an integral way and support large projects in the brain technology field.
  • The SwissNeuroRehab project is supported with the equivalent of over CHF11.2 million (USD12.2 million) over five years, 5.9 million provided by Innosuisse and the rest by the partners.
  • MindMaze is a global leader in digital neuro-therapeutics (DTx) solutions with a mission to accelerate the brains ability to recover, learn and adapt.

Novelis Launches Net Zero Lab to Develop Carbon-Neutral Solutions for Aluminium Manufacturing

Retrieved on: 
Monday, February 14, 2022
Zero, He's So Fine, University, Health, Ecosystem, CO2, Innovation Center station, Uncertainty, CEO, Risk, Aditya Birla Group, Novelis, Carbon, Form 10-K, Electric Bond and Share Company v. Securities and Exchange Commission, Solution, Recycling, Education, Alpine, HES-SO, R, Security (finance), Salgesch, Environment, Chief sustainability officer, Student, View, Symbiosis, Copper, Conthey, Partnership, Meta-Research Innovation Center at Stanford, Metal, Senior, Knowledge, Energy, Research, Sustainable development, Multimedia, Nature, News, Electricity, Industrial processes, Industry, Heart, Renewable energy, Engineering, EPFL

ZURICH, Feb. 14, 2022 /PRNewswire/ -- Novelis Inc., the world leader in aluminium rolling and recycling, today signed a long-term collaboration agreement with HES-SO Valais-Wallis in collaboration with EPFL of Energypolis Campus, a Swiss innovation and research hub, as well as energy distributor OIKEN, to start a joint research and development (R&D) laboratory to advance carbon neutral solutions for aluminium manufacturing.

Key Points: 
  • The R&D lab, named Net Zero Lab Valais, will be located at Novelis' plant in Sierre, Switzerland.
  • The work of the lab will focus on identifying and implementing innovative solutions to neutralize the carbon footprint of Novelis' manufacturing operations and neighboring communities, starting in Sierre.
  • "The Net Zero Lab Valais is another lever for increasing energy efficiency, reducing waste and supporting our communities.
  • "The Net Zero Lab Valais is an important initiative to help decarbonize the region," said Franois Fellay, CEO of OIKEN.